Treating osteoporosis with teriparatide: many unknowns?

Shukla V
Record ID 32003000854
English, French
Authors' objectives:

To summarize the available information on the use of teriparatide (rDNA origin) injections (Forteo(TM), manufactured by Eli Lilly and Company) to treat patients with osteoporosis who are at high risk for fracture.

Authors' recommendations: Because of the safety concerns and the lack of efficacy and effectiveness data, it is difficult to define teriparatide's role in the treatment of osteoporosis. This is compounded by the possible long-term antagonizing effect of bisphosphonates on teriparatide's bone-forming properties. Teriparatide may also be expensive.
Authors' methods: Overview
Project Status: Completed
URL for project:
Year Published: 2003
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Costs and Cost Analysis
  • Fractures, Bone
  • Osteoporosis
  • Teriparatide
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.